Abstract
BackgroundTranscatheter aortic valve implantation (TAVI) has become standard treatment for elderly patients with symptomatic severe aortic valve stenosis. The ACURATE neo AS study evaluates 30-day and 1-year clinical and hemodynamic outcomes in patients treated with the ACURATE neo2 valve.MethodsThe primary endpoint of this single-arm multicenter study is 30-day all-cause mortality. Other key endpoints include device performance, echocardiographic measures assessed by an independent core laboratory, and VARC-2 clinical efficacy and safety endpoints through 12 months.ResultsThe study enrolled 120 patients (mean age 82.1 ± 4.0 years; 67.5% female, mean baseline STS score 4.8 ± 3.8%). The VARC-2 composite safety endpoint at 30 days occurred in 13.3% of patients. All-cause mortality was 3.3% at 30 days and 11.9% at 1 year. The 30-day stroke rate was 2.5% (disabling stroke 1.7%); there were no new strokes between 30 days and 12 months. The rate of permanent pacemaker implantation was 15.0% (18/120) at 30 days and 17.8% (21/120) at 1 year. No patients required re-intervention for valve-related dysfunction and there were no cases of valve thrombosis or endocarditis. Patients demonstrated significant improvement in mean aortic valve gradient (baseline 38.9 ± 13.1 mmHg, 1 year 7.8 ± 3.5 mmHg; P < 0.001 in a paired analysis). In the overall population, paravalvular leak was evaluated at 1 year as none/trace in 60.5%, mild in 37.0%, and moderate in 2.5%; no patients had severe PVL.ConclusionsOne-year outcomes from the ACURATE neo AS study support the safety and performance of TAVI with the ACURATE neo2 valve.Graphic
Highlights
Transcatheter aortic valve implantation (TAVI), once reserved for patients who were inoperable or at high risk for surgical valve replacement, has recently been extended to intermediate- or low-risk populations
While clinical outcomes following TAVI are often comparable to those achieved surgically [1,2,3,4], there is some evidence that postTAVI complications such as patient–prosthesis-mismatch (PPM), paravalvular leak (PVL), and permanent pacemaker implantation (PPI) are associated with increased long-term mortality [5,6,7,8]
We report the results of the ACURATEneo AS study, which focused on clinical and core laboratoryassessed echocardiographic outcomes after 30 days and 12 months in patients with severe symptomatic aortic stenosis treated with the next-generation ACURATE neo2 valve
Summary
Transcatheter aortic valve implantation (TAVI), once reserved for patients who were inoperable or at high risk for surgical valve replacement, has recently been extended to intermediate- or low-risk populations. ACURATE neo has demonstrated favorable clinical and echocardiographic outcomes, with low rates of mortality and PPI [10, 11]. We report the results of the ACURATEneo AS study, which focused on clinical and core laboratoryassessed echocardiographic outcomes after 30 days and 12 months in patients with severe symptomatic aortic stenosis treated with the next-generation ACURATE neo valve. The ACURATE neo AS study evaluates 30-day and 1-year clinical and hemodynamic outcomes in patients treated with the ACURATEneo valve. Conclusions One-year outcomes from the ACURATE neo AS study support the safety and performance of TAVI with the ACURATE neo valve
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
